论文部分内容阅读
目的:通过检测Ⅱ型糖尿病(Diabetes mellitus)肾病和非肾病患者空腹血清游离脂肪酸(Free fatty acid,FFA)、24小时尿微量白蛋白(Urine micro albumin,UmALB)的水平,比较两组患者血清FFA与UmALB和空腹血糖的相关性。方法:采用OLYMPUS AU 5400全自动生化分析仪,取Ⅱ型糖尿病肾病和非肾病患者空腹静脉血、收集两组患者24小时尿,酶法检测血清游离脂肪酸、免疫透射比浊法检测尿微量白蛋白的水平。结果:Ⅱ型糖尿病肾病患者和非肾病患者UmALB比较有显著性差异(P<0.05),FFA比较无显著性差异(P>0.05),两组FFA和UmALB均高于正常对照组(P<0.05)。Ⅱ型糖尿病肾病组和非肾病组FFA与UmALB水平均无相关性,Ⅱ型糖尿病肾病组和非肾病组血糖与FFA均呈正相关(r1=0.441r2=0.433),糖尿病肾病组血糖与UmALB呈正相关(r=0.315)。结论:FFA在Ⅱ型糖尿病和糖尿病肾病中均有显著变化,UmALB的水平检测可作为临床Ⅱ型糖尿病肾病和非肾病鉴别诊断的生化指标,但血FFA和UmALB在糖尿病肾病中无显著相关性。
Objective: To detect the levels of fasting serum free fatty acid (FFA) and urinary microalbumin (UmALB) in patients with type 2 diabetes (Diabetes mellitus) and non-nephropathy Correlation with UmALB and fasting blood glucose. Methods: The OLYMPUS AU 5400 automatic biochemical analyzer was used to take fasting venous blood of patients with type 2 diabetic nephropathy and non-nephropathy. The urine of 24 hours in both groups was collected. The levels of serum free fatty acids were detected by enzyme-linked immunosorbent assay. Urine microalbumin s level. Results: There was significant difference in UmALB between type 2 diabetic nephropathy patients and non-nephropathy patients (P <0.05), but there was no significant difference in FFA between the two groups (P <0.05). The FFA and UmALB in both groups were significantly higher than those in control group ). No correlation was found between FFA and UmALB in type 2 diabetic nephropathy and non-nephrotic subjects. There was a positive correlation between FFA and UFA in patients with type 2 diabetic nephropathy and non-nephropathy (r1 = 0.441r2 = 0.433) (r = 0.315). CONCLUSION: FFA has significant changes in both type 2 diabetes mellitus and diabetic nephropathy. The level of UmALB can be used as a biochemical marker for the differential diagnosis of type 2 diabetic nephropathy and non-nephropathy. However, there is no significant correlation between serum FFA and UmALB in diabetic nephropathy.